Australia · Delayed Price · Currency is AUD Saluda Medical Earnings Call Transcripts
Fiscal Year 2026
-
Q3 saw 34% year-over-year revenue growth, driven by a 55% increase in U.S. patient implants and strong international performance. FY 2026 revenue guidance was raised to $87 million, with gross margin improvements expected from new product launches and operational efficiencies.
-
Saluda presented its closed-loop spinal cord stimulation technology, highlighting strong clinical outcomes, reduced therapy burden, and significant U.S. market expansion. Financial results show accelerating revenue, improved gross margins, and increased guidance for fiscal 2026.
-
Revenue grew 17% year-over-year to $39.4M in H1 FY26, with gross margin up to 49.4% and strong U.S. and international growth. FY26 revenue guidance reaffirmed at $85M, with improved cash burn and adjusted EBITDA expected.
Fiscal Year 2025
-
Raised AUD 231 million and began ASX trading to fund U.S. commercial expansion. Closed-loop spinal cord stimulation technology offers strong clinical outcomes, low therapy burden, and significant market opportunity, with a focus on rapid sales force growth and new reimbursement models.